Release Summary

EU Commission Approves BMS’s Opdivo (nivolumab) for Previously Treated Locally Advanced Unresectable or Metastatic Urothelial Carcinoma in Adults After Failure of Prior Platinum-Containing Therapy

Bristol-Myers Squibb Company